Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Platelet factor 4 mediates inflammation in experimental cerebral malaria

Loading...
Thumbnail Image

Date

Authors

Srivastava, Kalyan
Cockburn, Ian
Swaim, Anne Marie
Thompson, Laura E
Tripathi, Abhai
Fletcher, Craig A
Shirk, Erin M
Sun, Henry
Kowalska, Anna M
Fox-Talbot, Karen

Journal Title

Journal ISSN

Volume Title

Publisher

Cell Press

Abstract

Cerebral malaria (CM) is a major complication of Plasmodium falciparum infection in children. The pathogenesis of CM involves vascular inflammation, immune stimulation, and obstruction of cerebral capillaries. Platelets have a prominent role in both immune responses and vascular obstruction. We now demonstrate that the platelet-derived chemokine, platelet factor 4 (PF4)/CXCL4, promotes the development of experimental cerebral malaria (ECM). Plasmodium-infected red blood cells (RBCs) activated platelets independently of vascular effects, resulting in increased plasma PF4. PF4 or chemokine receptor CXCR3 null mice had less severe ECM, including decreased T cell recruitment to the brain, and platelet depletion or aspirin treatment reduced the development of ECM. We conclude that Plasmodium-infected RBCs can directly activate platelets, and platelet-derived PF4 then contributes to immune activation and T cell trafficking as part of the pathogenesis of ECM.

Description

Citation

Source

Cell Host and Microbe

Book Title

Entity type

Access Statement

License Rights

Restricted until

2037-12-31